Skip to main content
National AETC Support Center (NASC)
Homepage
  • Log in
Main navigation
  • About
    • About the AETC Program
    • ShareSpot: The AETC Blog
    • Quarterly Newsletter
    • Contact Us
    • AETC Program Faculty/Staff
  • Training
    • Training Overview
    • National HIV Curriculum
    • National RWHAP Clinical Conference
    • Residency Programs
    • Preceptorships
    • Self-Directed Learning
    • Webinar Recordings
  • Consultation
    • Consultation Overview
    • Request Technical Assistance
  • Directory
    • AETC Program Map
    • Practice Transformation
  • Resources
    • Explore Resources
    • Topic index
    • Guidelines
    • HIV Care Tools App
  • Calendar
  • Intranet
    • Your Updates and Requests
    • Program Branding
    • Evaluation Resources
    • FAQs
    • People Finder
    • TA Session Archive
    • CoPs

Breadcrumb

  1. Home

Search

Topics

  • Show all (1)
  • (-) Antiretroviral Therapy (ART) (1)
    • ART-Drug Interactions & Side Effects (1)

Type

  • ShareSpot Post (1)

Publication Date

  • Show all (1)
  • (-) 2013 (1)
Displaying 1 - 1 of 1

Cobicistat and Stribild Use in Patients with Renal Insufficiency

Profile picture for user ian.mcnicholl
Ian
McNicholl

ShareSpot Post, published 10/15/2013

Part of the Ryan White Network of TA sites:
  • Ryan White HIV/AIDS Program 
  • Target HIV 
  • Access, Care, and Engagement (ACE) TA Center 
  • Center for Quality Improvement & Innovation 
Subscribe to the NASC Newsletter

Footer Social Links

  • Facebook
  • Twitter (X)
  • YouTube
  • LinkedIn
  • Instagram
  • Flickr
  • Podcast
  • About
  • Training
  • Consultation & Help
  • Directory
  • Resources
  • Events
  • Login
  • Intranet
    • TA Sessions
    • People Finder
  • Intranet resources
    • Design Files, Templates & Resources
    • AETC National Evaluation Plan Documents

This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award (grant number U1O49824) totaling $1,915,000 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.

  • Site Policies